Gene expression profile derived from BRCA mutated ovarian cancers, termed “the BRCAness profile,” was found to correlate with platinum and PARP inhibitor sensitivity and was efficient in predicting platinum sensitivity of non-BRCA mutated ovarian cancers (Konstantinopoulos et al. 2010). Here, PARP1 is linked to ovarian carcinoma.